Antifungal susceptibility, risk factors and treatment outcomes of patients with candidemia at a university hospital in Saudi Arabia by Jiman-Fatani, Asif et al.
The InTernaTIonal arabIc Journal 
of anTImIcrobIal agenTs    Issn 2174-9094
© Under License of Creative Commons Attribution 3.0 License 1
2015
Vol. 5 No. 2:3 
doi: 10.3823/770
iMedPub Journals
http://journals.imed.pub
This article is available from: www.iajaa.org   /   www.medbrary.com
Antifungal susceptibility, risk 
factors and treatment outcomes 
of patients with candidemia at a 
university hospital in Saudi Arabia 1   Department of Medical Microbiology and Parasitology, Faculty of Medicine, 
King Abdulaziz University, Jeddah, 
Kingdom of Saudi Arabia.
2   Medical Microbiology and Immunology 
Department, Faculty of Medicine,  
Zagazig University, Egypt.
3   Clinical and Molecular Microbiology 
Laboratory, King Abdulaziz University 
Hospital, Jeddah, Kingdom of Saudi 
Arabia.
Corresponding author:
Dr. Takwa E. Meawed
 takwa_farid@hotmail.com
Asif Jiman-Fatani1,3,  
Dalia El-Hossary2,3 and 
Takwa E. Meawed2
Abstract
Background: Candidemia is a major cause of morbidity and mortality in 
hospitalized patients. The spectrum of candidemia has been changed 
especially among critically ill patients due to emergence of non-albicans 
Candida (NAC) species. The increasing use of azole agents is suggested 
to be responsible for this epidemiological shift. NAC species are of 
special concern because of their high drug-resistance and increasing 
prevalence.The aim of this study was to detect antifungal-susceptibility 
patterns, treatment outcomes and associated risk factors in patients 
with candidemia who were admitted to King Abdulaziz University 
Hospital (KAUH), Jeddah, Kingdom of Saudi Arabia (KSA) .
Methods: This work represents a cross sectional study done in the 
Clinical and Microbiology Laboratory at KAUH, during the period 
from March 2012 till February 2014 on a total of 141 patients with 
candidemia. They were 31(22%) Saudi and 110(87%) non-Saudi 
patients with age ranged from 1 day - 102 years. Blood cultures were 
collected for suspected cases of candidemia, followed by subculture 
on SDA. Identification was done by VITEK MS (MALDI-TOF MS), and 
confirmation of Candida isolates and antifungal-susceptibility testing 
were performed by using VITEK ®2 system.
Results: C.albicans isolates accounted for 39.7%, followed by C. 
tropicalis (21.3%), C. galabrata (18.4%) and C. parapsiliosis (14.9%). 
Additionally, C. dublinsis, C. krusei and C. famata were representing 
2.1%, 2.1% and 1.4%, respectively. All Candida isolates were 100% 
susceptible to amphotericin B. The best susceptibility to fluconazole 
was detected among each C. dubliensis and C. famata (100%). All C. 
krusei isolates were resistant to fluconazole, while they were susceptible 
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Introduction
Candida is by far the most common fungal 
pathogen found in bloodstream [1]. The incidence 
of candidemia has been increasing worldwide. The 
epidemiology of candidemia has been changed in 
the past decades due to use of immunosuppressive 
and cancer therapy, AIDS epidemic, patients 
receiving transplantation and the increasing use 
of antibacterial drugs in hospital settings and 
even in the community[2]. Mucosal colonization 
by Candida species, indwelling vascular catheters 
as central venous catheters, total parenteral 
nutrition, steroid therapy, abdominal surgery, and 
immunocompromised condition are also associated 
risk factors for candidemia [3,4].
Candidemia is becoming a major cause of 
morbidity and mortality in hospitalized patients. The 
spectrum of candidemia has been changed especially 
among critically ill patients due to emergence of 
non-albicans Candida (NAC) species, including C. 
tropicalis, C. parapsilosis, C. krusei, and C. glabrata. 
The increasing use of azole agents is suggested to 
be responsible for this epidemiological shift [5,6].
NAC species are of special concern because of 
their high drug-resistance and increasing prevalence 
in invasive candidiasis [7]. Several years ago, different 
studies have been reported about candidemia in 
hospitals of Saudi Arabia, and these studies have 
used different designs, prospective vs. retrospective 
and different patient groups (ICU vs. non-ICU) [8-12].
The aim of this study was to detect antifungal-
to other antifungal agents. All isolates were susceptible to flucytosine, 
except C. albicans and C. dubliensis which were susceptible 92.9% 
and 66.7%, respectively. All isolates were susceptible to itraconazol, 
except C. albicans and C. tropicalis which were susceptible 94.6% 
and 96.7%, respectively. The percentage of deceased patients with 
candidemia was significantly higher than the survivors among age 
group >64 years, particularly those who were mechanically ventilated 
and those understeroid therapy. The percentage of deceased patients 
was significantly higher than survivors among those admitted to adult 
ICUs (73.78%vs 26.23%) .
Conclusion: This study shows an epidemiological shift to higher NAC 
species isolation rates, with 100% susceptibility to amphotericin B in 
all isolates either C. albicans or NAC species, and 100% susceptibility 
to fluconazole among C. dubliensis and C. famata. Patients aged > 
64 years, admission to adult ICUs, mechanical ventilation and steroid 
therapy were significant risk factors for increased mortality due to 
candidemia.
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susceptibility patterns, treatment outcomes and 
associated risk factors in patients with candidemia 
who were admitted to King Abdulaziz University 
Hospital (KAUH), Jeddah, Kingdom of Saudi Arabia 
(KSA) .
Material and Methods
Study design and setting
A prospective cross-sectional study was done in 
the Clinical and Molecular Microbiology at KAUH 
from March 2012 through February 2014. 
Candidemia was defined according to study of 
Leon et al, [13] as at least one positive blood culture 
from peripheral line for Candida spp. in patients 
with clinical features of infection.
Ethical consideration
The study was approval by Research Ethics 
Committee, the Unit of Biomedical Ethics, Faculty 
of Medicine, King Abdulaziz University (Reference 
Number: 830-12).
Subjects
This study was included 141 hospitalized patients 
who were admitted in different units of KAUH. Their 
ages ranged from 1 day to 102 years with mean 
±sd (37.85±31.65) years, of these 63 (44.7%) were 
males and 78 (55.3%) females. They were 31 (22%) 
Saudis and 110 (78%) non-Saudis. Candidemia was 
diagnosed by isolation of Candida spp. from the 
blood culture of each patient.
Inclusion criteria
All candidemia cases which were considered 
as nosocomial infection included in the study by 
taking full patient’s history and clinical examination, 
laboratory investigations, assessment of risk factors 
and underlying diseases. Candidemia cases referred 
from other hospitals or patients with second attack 
of candidemia were excluded from this study.
Methods
Blood cultures were performed using automated 
blood culture system (BacT/Alert, Organon, Teknika, 
USA).A total of 10mls of each patient’s blood was 
inoculated into each bottle of blood culture system, 
one for aerobic and another for anaerobic growth. 
For pediatric patients, up to 5 mls of blood were 
inoculated into a single pediatric bottle. Culture 
bottles were loaded into BacT/Alert blood culture 
and kept until designated positive or for a maximum 
of 5 days incubation time. All bottles designated 
positive were smeared for Gram-stain. Culture 
bottles positive for yeast cells were subcultured on 
Sabouraud dextrose agar (SDA) (Saudi prepared 
media Laboratories, Riyadh, KSA) and the yeasts were 
identified with the use of VITEK MS at the same day 
if sufficient growth on SDA. The identification (ID) 
of Candida species is confirmed by using VITEK®2 
system for ID and antifungal-susceptibility testing 
(bioMerieux, Inc., France) [14].
Yeast identification and anti-fungal 
susceptibility testing by VITEK-2
The isolated pure colonies were selected from 
SDA and a purity plate was done to ensure that 
a pure culture was used for testing. A total of 
3 ml of 0.45% sterile saline were aseptically 
added into sterile plastic test tube. A sufficient 
number of morphologically similar colonies was 
transferred by a sterile loop to the saline tube 
and its density was checked by using Vitek 2 
DensiCheck which should be equivalent to (2) 
McFarland then, the suspension tube was placed 
in the cassette followed by an empty tube and the 
card for identification of yeast was placed in the 
suspension tube and the card for AST (AST-YS07) 
was placed in the empty tube. When the sample 
cycle was finished, the cassettes and the tubes 
were discarded. Minimal inhibitory concentration 
(MIC) was calculated and represented as (sensitive, 
intermediate or resistant) [15].
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Statistical analysis
Data were analyzed using Statistical Package for 
Social Sciences (SPSS) software, version 18. Chi-
square test was utilized to test for the association 
and/or difference between categorical variables. 
Yates’s correction was applied when appropriate. 
Odds ratio and 95% confidence interval were 
calculated. Continuous variables were presented as 
mean, standard deviation and range. P value less 
than 0.05 was considered statistically significant. 
Results
Demographic data of the 141 patients with 
candidemia are presented in Table (1). There were 
31(22%) Saudis, and 110(78%) non-Saudis. A total 
of 85(60.3%) patients were deceased following 
candidemia. High rates of patients were aged < 1 
year (40; 28.4%) or aged >64 (35;24.8%). A total 
of (85; 60.3%) patients were deceased following 
candidemia (Table 1). C. albicans was the most 
Received on 28-09-2015 Accepted on 10-11-2015    This article is available from: www.iajaa.org   /   www.medbrary.com 
Table 1. Demographic data of 141 patients with 
candidemia.
No.(%)Item
40(28.4%)
11(7.8%)
28(19.9%)
27(19.1%)
35(24.8%)
Age  groups
< 1 year
1-18
19-49
50-64
>64
63(44.7%)
78(55.3%)
Sex
Males
Females
31(22.0%)
110(78.0%)
Nationality
Saudi
Non-Saudi
61(43.2%)
32(22.7%)
34(24.1%)
14(9.9%)
Wards
Adult ICUs
Pediatric ICU 
Adult wards
Pediatric wards
85(60.3%)
56(39.7%)
Outcome
Deceased
Survived
Table 2. Species distribution  and susceptibility patterns of Candida isolates to anti-fungal drugs.
% susceptible to 
Itraconazole
% susceptible to 
Flucytosine
% susceptible to 
Fluconazole
% susceptible to 
Amphotericin-B
Candida species  
(no/%)
94.692.994.6100C. albicans (56/39.7)
10010092.3100C. galabrata (26/18.4)
96.710096.7100C. tropicalis ( 30/21.3)
10010095.2100C. parapsiliosis ( 21/14.9)
10066.7100100C. dublinsis (3/2.1)
100100 0.0 100C. krusi  (3/2.1)
100100100100C. famata  (2/1.4)
 137(97.2%) 136(96.5%)  131(92.9%) 141(100%)Total no.(141)
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common species detected (39.7%), followed by 
C. tropicalis (21.3%), C. galabrata (18.4%) and C. 
parapsiliosis (14.9%). However, C. dublinsis, C. krusei 
and C. famata were represented by 2.1%, 2.1% and 
96.7% susceptible, respectively (Table 2).
All Candida isolates were 100% susceptible to 
amphotericin B. The best susceptibility to fluconazole 
was detected among C. dubliensis and C.famata 
(100%). C. krusei isolates were 100% resistant to 
fluconazole, but these were 100% susceptible to other 
antifungal agents. All isolates were susceptible to 
flucytosine, except C. albicans and C. dubliensis which 
were 92.9% and 66.7% susceptible, respectively. All 
isolates were susceptible to itraconazole, except C. 
albicans and C. tropicalis which were 94.6% and 
96.7% susceptible, respectively. (Table 2).
The percentage of deceased patients was 
significantly higher among those who were 
mechanically ventilated (72.6% vs 27.4%), and 
who received steroid therapy than others (90.9% 
vs 9.1%). There was an increased risk of mortality 
in candidemic patients who were under dialysis, 
have CVC, chronic renal impairment, heart 
diseases, diabetes mellitus and those with long stay 
in hospital (>20 days) or infected/colonized with 
Candida (Table 3). The percentage of deceased 
Table 3. Risk factors, underlying diseases and their effects on the outcome of candidemia patients
OR 95%CIp-valuex2Survived
N=56
Deceased
N=85
Patients (total: 141)
1.78(0.79-4.05)
0.65(0.25-1.5)
4.68(4.68-10.6)
0.49(0.23-1.07)
1.11(0.51-2.40)
8.31(1.75-53.1)
0.41(0.10-1.63)
1.79(0.59-5.58)
1.31(0.43-4.2)
2.36(0.91-6.31)
2.03(0.83-5.03)
0.12
0.27
0.001**
0.051
0.78
0.001**
0.14
0.25
0.60
0.052
0.089
2.3
1.21
17.5
3.79
0.07
10.2
2.11
1.28
0.27
3.74
2.85
 
37(35.9%)
43(42.6%)
 25 (27.4%)
 24(51.1%)
37(38.95%)
2(9.1%)
6(54.55%)
6(28.57%)
6(30.0%)
8(25.0%)
10(27.8%)
66(64.08%)
58(57.4%)
69(72.6%)
23(48.9%)
58(61.05%)
20(90.9%)   
5(45.45%)
15(71.43%)
14(70.0%) 
24(75.0%) 
26(72.2%)
Risk factors
1-CVC; 103(73%)
2-Urinary catheter; 101(71.6%)
3-M.V; 95(67.4%)
4-TPN; 47(33.3%)
5-Anti-bacterials; 95(67.4%)
6-Steroid therapy; 22(15.6%)
7-Prematurity; 11(7.8%)
8-Dialysis; 21(14.9%)
9-Liver impairment; 20(14.2%)
10-Candiduria ; 32(22.7%)
11-Candida in tracheal aspirate; 36(25.5%)
12-length of hospital stay before candidemia; 
(23.82±18.34 days,range,1-84)
1.97(0.35-14.3)
1.33(0.09-37)
0.99(0.34-2.88)
0.98(0.13-8.6)
0.98(0.13-8.6)
0.92(0.24-3.5)
1.59(0.35-8.15)
---------------
1.57(0.61-4.13)
----------------
----------------
0.40
0.81
0.97
0.97
0.97
0.88
0.51
0.24
0.30
0.015*
0.21
0.70
0.05
0.001
0.001
0.001
0.02
0.42
1.43
1.04
6.25
1.52
2(22.2%)
1(33.3%) 
8(40.0%)
2(40.0%)
2(40.0%)
5(41.6%)
3(30.0%)
0.0(0.0%)
9(31.04%)
4(100.0%)
1(100.0%)
7(77.8%)
2(66.7%)
12(60.0%)
3(60.0%)
3(60.0%)
7(58.3%)
7(70.0%)
2(100.0%)
20(68.96%) 
0.0(0.0%)
0.0(0.0%)
Underlaying diseases
1-Chronic Renal Impairment; 9(6.4 %)
2-Chronic Liver Disease; 3(2.1%) 
3-Solid Malignancy; 20(14.2%) 
4-Hematological Malignancy; 5(3.5%) 
5-Chemotherapy; 5(3.5%)
6-Respiratory Diseases; 12(8.5%) 
7-Heart diseases; 10(7.1%) 
8-Human Immunodeficiency Virus;2(1.4%) 
9-Diabetes Mellitus; 29(20.6%) 
10-Intestinal Obstruction; 4(2.8%)
11-Stroke; 1(0.7%) 
*Significant; **Highly Significant; OR: Odds ratio; CI: Confidance interval
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Table 4. Details of risk factors associated with the outcome of 141 candidemia cases
OR 95%CIp-valuex2Survived
No. (56;39.7%)
Deceased
No.(85;60.3%) Patients  
1.7(0.48-2.37)
0.35(0.08-1.41)
0.59(0.24-1.47)
1.4(0.54-3.7)
2.85(1.15-7.22)
0.85
0.91
0.21
0.45
0.015*
0.03
2.85
1.54
0.57
6.23
17(42.5%)
7(63.64%)
 14(50.0%)
 9(33.3%)
9(23.07%)
 23(57.5%)
 4(36.36%) 
 14(50.0%)
 18(66.7%) 
 30(76.9%)
Age  group (no)
< 1 year (40)
1-18 (11)
19-49  (28)
50-64 (27)
>64 (39)
1.63(0.77-3.44)
0.6(0.29-1.29)
0.16
0.16
1.94
1.94
 21(33.3%) 
 35(44.9%)
 42(66.7%)
 43(55.1%)
Sex
Males (63)
Females (78)
1.51(0.6-3.82)
0.66(0.26-1.65)
0.33
0.33
0.92
0.92
 10(32.3%)
 46(41.8%)
21(67.7%)
64(58.2%)
Nationality
Saudi  (31)
Non Saudi (110)
2.81(1.29-6.17)
1.31(0.54-3.25)
0.53(0.23-1.22)
0.23(0.06-0.85)
0.004**
0.51
0.10
0.012*
2.81
0.42
2.64
6.53
16(26.23%)
11(34.4%)
19(55.89%)
10(71.4%)
45(73.78%)
21(65.6%)
15(44.1%)
4(28.6%)
Ward
Adult ICU; 61 (43.2%)
Pediatric ICU; 32 (22.7%)
Adult ward; 34(24.11%)
Pediatric ward; 14 (9.9%)
0.48(0.17-1.33)
0.31(0.09-0.99)
2.01(0.62-6.8)
0.91(0.34-2.42)
1.85(0.87-3.96)
0.13
0.02*
0.19
0.83
0.11
2.27
5.04
1.65
0.05
2.43
11(55.5%)
11(64.7%)
5(26.3%)
10(41.7%)
19(31.1%)
9(45.0%)
6(35.3%)
14(73.7%)
14(58.3%)
42(68. 9%)
Length of stay
From 1-5 days; 20(14.2%)
From 6-10 days; 17(12.1%)
From 11-15 days; 19(13.5%)
From 16-20 days; 24(17%)
More than 20 days; 61(43.3%)
*Significant; **Highly significant; OR: Odds ratio; CI: Confidance interval.
patients was significantly higher in patients aged 
≥ 64 years than younger ages  (76.9% vs 23.07%) 
(Table 4).
The percentage of deceased patients in adult ICU 
was significantly higher than the survivors (73.78% 
vs 26.23%) (Table 4). There were no significant 
differences between deceased and survived 
candidemia patients infected with different Candida 
species (Table 5).
Discussion
Candida bloodstream infection (CBSI) represents 
an important problem in critically ill hospitalized 
patients. (CBSI) is often a consequence of long 
term use of broad-spectrum antibacterial therapy, 
complex surgical procedures and invasive medical 
devices. The epidemiology of candidemia is changing 
with an increase in the proportion of NAC [16].
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Table 5.Outcome of patients with candidemia according to Candida species
OR 95%CIp-valuex2Survived
No.(%)
Deceased
No.( %)
Species (no.)
1.44(0.67-3.08)0.361.0420(35.7)36(64.3)C. albicans (56)
1.42(0.56-3.6)0.420.4210(33.320(66.7)C. tropicalis (30)
0.74(0.29-1.91)0.490.7412(46.214(53.8)C. galabrata (26)
0.55(0.19-1.52)1.650.1911(52.4)10(47.6)C. parapsiliosis (21)
1.33(0.09-37.88)0.810.051(33.3)2(66.7)C. dublinsis (3)
1.33(0.09-37.88)0.810.051(33.3)2(66.7)C. Krusei (3)
0.65(0.02-24.5)0.760.091(50 )1(50)C. famata (2)
During the current study; overall mortality 
associated with candidemia was 60.3 % (Table 1). 
Other researchers reported similar results to our with 
overall crude mortality among their patients with 
invasive candidiasis or candidemia in the range of 
40 - 60% [17-19]. A previous Saudi study reported 
that approximately two-fifths (40.6%) of the patients 
died within 30-days after isolation of Candida species 
from their sterile body sites [20]. Kumar et al. [21] 
in Pakistan, reported lower mortality rate (23.4%) 
in their study [21], and Playford et al. [22], reported 
higher mortality rate associated with candidemia due 
to NAC (80%) among non-neutropenic critically ill 
patients admitted to ICU.
This current study showed that C. albicans was 
the predominant isolate in patients with candidemia 
(39.7%), while all other Candida species (NAC) were 
responsible for 60.3% of the cases, and the most 
common NAC species was C. tropicalis (21.3%) 
among all isolates (Table2). However, an earlier 
study done by Akbar and Tahawi [9] at the same 
hospital (KAUH) reported that C. albicans was the 
most frequently isolated species (71%), followed by 
C. tropicalis (13%) and C. parapsilosis (13%).Both 
studies showed that the most common species was 
C. albicans , followed by C. tropicalis, whereas the 
study of Bukharie et al [8] in Saudi Arabia, has found 
that C. albicans caused 19% of candidemia cases .
Al- Thaqafi et al. [23],demonstrated that the total 
number of candidemia cases at King Abdulaziz Medical 
City (KAMC) in Jeddah during an 8-year period (2002 
-2009) was relatively higher than previously reported 
data from other regions of Saudi Arabia .
Eksi et al. [24] in Turkey, found that 47.7% 
of their isolates from candidemia cases were C. 
albicans, followed by C. parapsilosis (36.9%) and 
other Candida species represented by 15.4%. 
Chi et al. [7] in Taiwan, reported that C. albicans 
represented 43.5%, meanwhile, non-albicans spp. 
including C.glabrata, C.tropicalis, C. parapsilosis, 
C.kruseiandC. heamulonii were responsible for 
(56.5%) of candidemia cases [7]. Montagna et al. 
[13] in Italy, reported that 59.8 % of their studied 
candidemia cases were caused by NAC, and C. 
parapsilosis was the most common species. Also, 
the study of De Luca et al. [25]in Italy, found that C. 
albicans represented 48% of isolates in candidemia 
cases, while all other NAC was represented by 52% 
and the most common species was C. glabrata. The 
highest prevalence of NAC was found by Kumar 
et al. [21] in Pakistan, where NAC species were 
isolated in 90.9% of candidemic patients including 
C. parapsilosis (36.4%), C. lusitaniae (29.9%), C. 
tropicalis (20.8%), C. glabrata (3.9%), and only 7 
patients (9.1%) were having C. albicans. This finding 
showed that C. albicans is less common in certain 
countries than others and there is an etiological 
shift to higher isolation of NAC species in most 
candidemic patients which has been also observed 
in our study.
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Antifungal susceptibility is highly important for 
management of patients with candidemia. The 
results of this study showed that all isolated Candida 
species were susceptible to amphotericin B, which is in 
agreement with the results of many other studies [24-
25]. However, the increased usage of antifungal agents 
may contribute to increased occurrence of resistance in 
some Candida species more than others [26].
In general, our antifungal susceptibility results 
were comparable to that reported by Pfllar et al., 
[27], their study observed that fluconazole-resistance 
was extremely rare (1%) among blood isolates of 
C. albicans, C. tropicalis, C. parapsilosis, while C. 
lusitaniae and C. glabrata exhibited 2% and 8% 
resistance to fluconazole, respectively.
Al Thaqafi et al. [23] in Saudi Arabia, found that 
fluconazole-susceptibility was 38.5% for C. albicans 
and 52.5% for other Candida species, while an 
Egyptian study of Mohtady et al. [28] reported that 
fluconazole-resistant C. dubliniensis and C. albicans 
were (55.6%) and (49%), respectively. Omrani et 
al.,[20], found that more than 90% of C.albicans, C. 
parapsilosis, and C. tropicalis isolates in their study 
were susceptible to fluconazole and caspofungin. 
Moreover, the vast majority of Candida isolates 
were susceptible to voriconazole and amphotericin 
B, while 33.3% of C. krusei isolates were resistant 
to caspofungin. These data were comparable to our 
results, especially that all Candida isolates in this study 
were susceptible to voriconazole and caspofungin.
In agreement with our overall results, De Luca 
et al. [25], has found that all Candida species were 
susceptible to amphotericin B, whereas C. albicans 
and C. parapsilosis susceptibility to fluconazole was 
100%, with decreased susceptibility of C. glabrata 
to 76.5%. In addition, Ajenjoet al. [29], indicated 
that 88.8% of their Candida spp. isolates were 
fluconazole-susceptible.
The increase incidence of Candida infections 
contribute to increased usage of antifungal and 
more developing of resistance in Candida species 
[26]. Therefore, early and adequate empirical anti-
fungal treatment plus early removal of central 
catheters are considered the main factors to reduce 
use of antifungal drugs, morbidity and mortality. It 
is necessary to implement guidelines of empirical 
antifungal treatment in patients with highly risk 
factors of developing candidemia [30].
The role of intravascular catheters in causing 
candidemia has been documented. Removal of 
vascular catheters has been advocated as an adjunctive 
strategy for treating patients with catheter-related 
candidemia [31]. This study showed that most 
patients (73%) with central venous catheters (CVCs) 
and those who received antibacterials (67.4%) had 
developed candidemia (Table 3). A previous study 
done at the same hospital by Akbar and Tahawi [9], 
found that patients with CVCs (77%) who received 
broad-spectrum antibacterial therapy (87%) were 
associated with candidemia. The study of Chander 
et al. [6], has similar results to ours regarding 
associated risk factors with candidemia.
Other associated risk factors for candidemia 
observed in this study included; age < 1 year > 
64 years, urinary catheter, mechanical ventilation, 
undergoing dialysis, steroid therapy, and prolonged 
hospital stay for >20 days as shown in Table 3 & 4. 
The study of Montagna et al. [16], reported similar 
risk factors in their patients especially due to using 
of Hickman catheter and length of stay in ICU.
The present study shows that the incidence of C. 
albicans and C. glabrata was is higher among patients 
with solid compared to hematological malignancies, 
while the incidence of other non-albicans Candida 
species was also higher among patients with 
hematological than solid malignancies. Al-Thaqafi, et 
al.[23], reported in their study of over 8-year-duration at 
King Abdulaziz Medical City, Jeddah, that malignancy 
was significantly associated with the development of 
non-albicans Candida species. 
 The study of Kontoyiannis et al.[32], 
concluded that immunocompromised patients 
including those affected by solid tumors or 
haematological malignancies are at high risk for 
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developing  Candida  infection. Additionally, the 
widespread use of fluconazole prophylaxis in 
haematological and stem cell transplant settings 
might be responsible for a decreased incidence of 
invasive Candida infections in these populations.
This study found that the rate of deceased patients 
was higher than Survived ones to candidemia with C. 
albicans (64.3% vs 35.7%) or NAC (57.6% vs 42.4%), 
with no significant differences between the two groups 
(Table 5). However, a study in Greece, found the 
overall mortality to be significantly higher in patients 
with NAC species than C. albicans associated with 
bloodstream infections (90% vs 52.8%) [33]. Kelvay 
et al.[34], recorded that mortality associated with C. 
albicans and C. glabrata candidaemia was 44% and 
41%, respectively. Other studies reported higher rates 
of mortality in association with NAC species, especially 
C. krusei, C. glabrataand C. tropicalis [35-38].
This study concludes that there is an 
epidemiological shift to higher isolation of NAC 
species in candidemic patients and all Candida and 
NAC isolates were susceptible to amphotericin B. 
Additionally, increased mortality was observed in 
patients older than 64 years, with steroid therapy, 
mechanical ventilation and those who admitted to 
adult ICU. 
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